F45 Training Expands Services Amid Growing Demand for GLP-1 Weight-Loss Solutions
Krissy Vann | Host, All Things Fitness and Wellness
The use of GLP-1 receptor agonists, such as Semaglutide and Tirzepatide, is reshaping how individuals approach weight loss. Originally developed to treat Type 2 diabetes, these medications have become widely recognized for their ability to suppress appetite and regulate blood sugar, often leading to significant weight reduction. According to the CDC, the prevalence of adult obesity in the United States is 42.4%, underscoring the demand for effective weight-loss solutions.
Research has raised concerns that weight loss from GLP-1 medications may include a loss of muscle mass. One study published in the Journal of Clinical Endocrinology & Metabolism noted that lean body mass can account for a notable proportion of weight lost during treatment if not accompanied by resistance training and proper nutrition. This concern has spurred fitness and wellness companies to integrate structured exercise and dietary guidance into weight management strategies.
F45 has announced an expansion of its partnership with telehealth provider Dr. B. This collaboration offers a program combining GLP-1 prescriptions with F45’s fitness and nutrition tools. The initiative aims to support individuals in maintaining muscle mass and achieving sustainable weight-loss outcomes.
“GLP-1 medication is not suitable for everyone, but it can be a valuable tool for some individuals on their weight-loss journey,” said Tom Dowd, CEO of F45 Training. “This partnership ensures access to resistance training and nutrition programs essential for successful outcomes.”
The program, available for $249 per month, includes consultations with licensed medical providers, prescription medications shipped directly to participants, and access to F45’s app. The app features on-demand workouts, curated nutrition plans, and tools to track progress. Participants can also access discounts on F45 in-studio memberships and use pre-tax HSA/FSA funds for expenses with a provided Letter of Medical Necessity.
Dr. B Founder and CEO Cyrus Massoumi highlighted the importance of a well-rounded approach. “GLP-1 medications empower many people to lose weight and reduce their cardio-metabolic risk factors, but medication is only part of the equation. Promoting behaviors that lead to sustainable health and longevity is our goal.”
This partnership reflects a growing trend of fitness companies stepping into the healthcare space, integrating medical offerings with traditional wellness programs. As GLP-1 medications gain traction, such collaborations demonstrate how the fitness industry is increasingly addressing weight management through a combination of medical and fitness-based approaches.
Elevate Your Expertise: Tune in to Our YouTube Channel for Exclusive Podcasts with fitness and wellness Industry Titans and Game-Changers
